UNSPSC 51145303: Prolintane

This classification denotes a central nervous system stimulant with the molecular formula C15H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) EM4YZW677H, chemically known as pyrrolidine, 1-(.alpha.-propylphenethyl)-, hydrochloride but more generally known as prolintane, which bears US NIH Compound Identifier 14592. European Medicines Agency schedules Prolintane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10083MIG.

UNSPSC 51145303 Prolintane is a Commodity code that nominally identifies a specific psychostimulant pharmaceutical; however, the recent state and local procurement activity posted under this code does not match the narrow chemical classification. Instead, the code appears in solicitations for broad pharmaceutical procurement — including naloxone distribution, generic multi-source drugs and OTC products through cooperative purchasing, and pharmacy benefit program modernization. State and local issuing bodies are treating this code as a general pharmaceutical-acquisition umbrella rather than a category specific to prolintane formulations. The work actually being solicited includes supply agreements for anti-opioid medications, generic pharmaceuticals sold through authorized wholesaler networks, and strategic consulting on direct-to-manufacturer prescription fulfillment models. Issuing bodies span state health and human services departments, county public health operations, and multistate cooperative purchasing alliances.

The most recent activity shows geographic spread across Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, including all shipping and handling costs in vendor bids; the contract carries a two-year initial term with a one-year renewal option and requires E-Verify compliance, workers' compensation insurance, and commercial general liability coverage. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, seeking information on direct contracting capacity with self-insured health plans and value-based pricing models outside traditional PBM and GPO arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP posted January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, requiring NDC-level product specifications, distribution through three authorized wholesalers, cGMP and DSCSA certification, and pricing submissions weighted 75 percent on competitiveness, with a two-year contract term effective July 1, 2026.